{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:12Z","timestamp":1787032872635,"version":"build-2736575974"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,31]]},"DOI":"10.7759\/cureus.81542","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T23:48:01Z","timestamp":1743464881000},"source":"Crossref","is-referenced-by-count":1,"title":["Multiple Cutaneous Adverse Reactions Secondary to Nivolumab Therapy in an Elderly Male"],"prefix":"10.7759","author":[{"given":"Divya","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Bains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Vedant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19750","article-title":"Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors","volume":"185","author":"Gault A","year":"2021","unstructured":"Gault A, Anderson AE, Plummer R, Stewart C, Pratt AG, Rajan N. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. Br J Dermatol. 2021, 185:263-71. 10.1111\/bjd.19750","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13399","article-title":"Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma","volume":"43","author":"Adler NR","year":"2018","unstructured":"Adler NR, Murray WK, Brady B, McCormack C, Pan Y. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma. Clin Exp Dermatol. 2018, 43:497-9. 10.1111\/ced.13399","journal-title":"Clin Exp Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.022","article-title":"Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma","volume":"70","author":"Kyllo RL","year":"2014","unstructured":"Kyllo RL, Parker MK, Rosman I, Musiek AC. Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol. 2014, 70:85-6. 10.1016\/j.jaad.2013.11.022","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins LK","year":"2017","unstructured":"Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017, 41:125-8. 10.1016\/j.currproblcancer.2016.12.001","journal-title":"Curr Probl Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341697-multiple-cutaneous-adverse-reactions-secondary-to-nivolumab-therapy-in-an-elderly-male","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T23:48:02Z","timestamp":1743464882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341697-multiple-cutaneous-adverse-reactions-secondary-to-nivolumab-therapy-in-an-elderly-male"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":4,"URL":"https:\/\/doi.org\/10.7759\/cureus.81542","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}